Abstract. In the present study, we analyzed in vitro effects of natural and synthetic triorganotin ligands of nuclear retinoid X receptors in human MCF-7 breast cancer cells. Our data has shown that all-trans retinoic acid significantly reduced expression of RXRalpha mRNA, Bcl2 and enhanced expression of BAX proteins. Tributyltin bromide markedly decreased mRNA level of RXRalpha and RXRbeta. Significantly reduced levels of both RXRs proteins were observed after treatment with tributyltin chloride (TBT-Cl) but not after treatment with triphenyltin chloride (TPT-Cl) for RXRbeta protein. Both RXRalpha and RXRbeta protein levels decrease was found also by combination ATRA+TBT-Cl/TPT-Cl.
Retinoids and rexinoids play an important role in regulation of growth, differentiation, metabolism and morphogenesis in higher vertebrates and humans. These effects are mediated through their nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) and their coregulators. RXRs play unique modulatory and integrative roles across multiple regulatory systems. It is well known that nuclear receptors of hormones and biologically active ligands can be affected by a number of endocrine disrupting chemicals. Organotin compounds are typical environmental contaminants used as biocides, agricultural fungicides, wood preservatives, and special paints for marine vessels and suspected endocrine-disrupting substances (Nakanishi 2008; Brtko and Dvorak 2015; Hiromori et al. 2016; . A remarkable breakthrough in the field came out with the recent findings that triorganotin compounds are agonists of RXR subtypes of nuclear receptors ( Fig. 1) (Delgado Filho et al. 2011; Grun 2014) . Since RXRs can act predominantly as heterodimeric partners of a number of other nuclear receptors, including retinoic acid receptors (RARs), then RXR subtypes may play an important role in the modulation of many hormonal signals and regulatory pathways within the target cells Dvorak 2011, 2015) .
We have recently shown that either tributyltin chloride (TBT-Cl) or triphenyltin chloride (TPT-Cl) is capable to compete for 9-cis retinoic acid (9cRA) binding sites on the RXR molecule nearly to the same degree as 9cRA (Toporova et al. 2016a) . We examined the RXR-binding capability of wide range of commercially available triorganotin derivatives represented by tributyltin derivatives: TBT-Cl, tributyltin bromide (TBT-Br), tributyltin iodide (TBT-I); tributyltin hydride (TBT-H) and triphenyltin derivatives: TPT-Cl and triphenyltin hydride (TPT-H) (Sigma, Germany). We performed series of binding experiments (method described in ), where we measured binding ability of all investigated tributyltin derivatives in following order: TBT-Cl > TBT-Br > TBT-I (Toporova et al. 2016b ). Hydrides of trialkyltin-and triphenyltin derivates showed very little RXR-binding capability.
Moreover, using proteomics analyses, we have detected several proteins -the specific breast cancer biomarkersdifferentially expressed in MCF-7 cells after treatment with all-trans retinoic acid (ATRA) and 9cRA isomers (Flodrova et al. 2013) .
Based on these data we performed several series of in vitro experiments in order to evaluate potential effects of various tributyl-and triphenyltin derivates alone and in combination with retinoic acid. The MCF-7 human breast cancer cell line were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine se-rum (FBS), antibiotics (penicillin, streptomycin, gentamicin) and cultured in humidified atmosphere of 5% CO 2 and 95% air at 37°C. Cells were exposed to 100 nM concentrations of tributyltin and triphenyltin derivates (TBT-Cl, TBT-Br, TBT-I, TBT-H, and TPT-Cl, TPT-H), 9cRA (100 nM) (Sigma, Germany) and/or to ATRA (1 and 10 µM) for 48 hours. Stock solution of all compounds was originally dissolved in ethanol, and an equal volume of ethanol (final concentration <0.02%) was added to the control cells. The cells subsequently underwent both semiquantitative real-time PCR analyses of RXRalpha and RXRbeta nuclear receptors and selected genes of apoptosis (Bcl2 and BAX) (method described in Hunakova et al. 2016) and Western blot analyses of proteins: RXRalpha, RXRbeta, Bcl2 and BAX. Nuclear proteins were isolated using Nuclear extraction kit (Abcam, USA) according to manufacturer's instructions. Fluorescent Western blot analyses were performed using Odyssey reagents (Li-Cor, USA) and specific primary antibodies (Abcam, USA) according to manufacturers' instructions. The results were analysed by Image Studio software for Odyssey infrared imaging system (Li-Cor, USA).
On mRNA level, 10 µM ATRA significantly reduced expression of RXRalpha mRNA. Combination of 10 µM ATRA with 9cRA significantly reduced expression of RXRalpha and RXRbeta (Table 1 ) when compared to mock-treated cells. ATRA (1 µM) or 9cRA (100 nM) alone did not affect expression of any RXRs.
We have already shown that 48 h treatment with TBT-Cl significantly reduced expression of RXRalpha and RXR- beta mRNA (Hunakova et al. 2016) . The similar significant reduction of RXRalpha and RXRbeta mRNA was observed after treatment with tributyltin bromide TBT-Br (Table 1) . Combination of tributyltin derivates with 10 µM ATRA significantly reduced expression of RXRalpha and RXRbeta mRNA (p < 0.05) when compared to mock and 1 µM ATRAtreated cells (Table 1) , which is consistent with combination 10 µM ATRA + natural RXR ligand (9cRA). However, we did not find any effects of triphenyltin derivates on rexinoid receptors on mRNA level. Since effects on RXRs mRNA levels of ATRA + triorganotin derivate combination could be the result of concentration of 10 µM ATRA in this combination, we have decided to use lower concentration of ATRA and performed protein Western blot analyses of the combination 1 µM ATRA + 100 nM 9cRA and two of the strongest RXR-binding derivates: TBT-Cl and TPT-Cl. Treatment with 1 µM ATRA significantly reduced protein level of RXRalpha and RXRbeta when compared to mock treated cells (Fig. 2) . 100 nM 9cRA did not affect RXRalpha or RXRbeta at the protein level. On the other hand, the significantly reduced levels of RXRalpha and RXRbeta proteins were observed after treatment with TBT-Cl but not after treatment with TPT-Cl for RXRbeta protein. Both RXRalpha and RXRbeta protein levels decrease was found also by combination ATRA+TBT-Cl/TPT-Cl (p < 0.05).
The discrepancy between mRNA and proteins levels of selected genes could be due to earlier onset and faster response of mRNA levels on retinoic acids when compared to protein levels after 48 hours of treatment.
Recently, we have confirmed the significant reduction of viable cells in both MCF-7 and MDA-MB-231 cell lines accompanied the increase of late apoptosis proportion/percentage in MCF-7 cells after 17 hours treatment with 200 nM TBT-Cl and 800 nM TPT-Cl (Hunakova et al. 2016 ). Since retinoic acids are involved in various processes including carcinogenesis, apoptosis and differentiation, the aim of this study was also the evaluation of effects of triorganotin derivates on Bcl2 and BAX mRNA and protein levels.
ATRA (1 µM or 10 µM), TBT-Cl and TBT-Br (100 nM) significantly reduced expression of Bcl2 mRNA when compared to mock-treated cells. However, 9cRA, TBT-I and TBT-H and triphenyltin derivates did not affect this mRNA expression (data not shown). Combination of 10 µM ATRA with tributyltin derivates significantly reduced Bcl2 mRNA expression (p < 0.05) ( Table 1) .
Western blot analyses showed significantly reduced Bcl2 protein levels after treatment with 1 µM ATRA, 100 nM 9cRA, 100 nM TBT-Cl and 100 nM TPT-Cl when compared to mock-treated cells (p < 0.05) ( Table 2) . Treatment with combination of ATRA+9cRA resulted in significant reduction when compared to treatment with retinoic acids alone. Moreover ATRA+TBT-Cl caused even more reduction when compared to cells treated with ATRA or TBT-Cl alone (p < 0.05). Fickova et al. (2015) showed similar decreased of Bcl2 
Group
Bcl2 BAX Control 1.00 ± 0.00 1.00 ± 0.00 ATRA (1 µM) 0.28 ± 0.07* 1.43 ± 0.15* 9cRA (100 nM) 0.40 ± 0.21* 2.5 ± 0.88* ATRA (1 µM) + 9cRA (100 nM) 0.16 ± 0.02* 1.08 ± 0.02 TBT-Cl (100 nM) 0.23 ± 0.02* 0.67 ± 0.01* ATRA (10 µM) + TBT-Cl (100 nM) 0.42 ± 0.39* 1.03 ± 0.35 TPT-Cl (100 nM) 0.11 ± 0.06* 1.34 ± 0.62 ATRA (10 µM) + TPT-Cl (100 nM) 0.16 ± 0.07* 1.78 ± 0.41* *p < 0.05 vs. Control group. 
RXRalpha protein RXRbeta protein
Normalized to Beta-actin Normalized to Beta-actin protein levels (TBT-Cl) on MCF-7 cells but with different experimental cell culture approach. 1 µM and 10 µM ATRA (p < 0.05) significantly induced expression of BAX mRNA. Combination of 10 µM ATRA with TBT-I and TBT-H significantly induced expression of BAX (Table 1) . No effect was observed after treatment with triorganotin derivates.
Retinoic acids alone significantly increased BAX protein levels (Table 2) . On the other hand TBT-Cl decreased this protein. However, since TBT-Cl significantly reduced Bcl2 levels, the BAX/Bcl2 protein ratio is in favour of BAX protein.
Based on the results obtained in these series of experiment we might consider triorganotin chlorides (TBT-Cl and TPTCl) as the potent RXR ligands comparable to natural rexinoid -9cRA. These characteristics enable to open a new research sub-area on novel organotin compounds with new leads for the development of RXR ligands with anti-tumour properties.
